My 2022 picks for the Silicon Investor Charity Contest are:
• ENTA 20%: Large position in my real portfolio.
• RVNC 20%: Ditto. (Fixing the manufacturing problem and resubmitting the Daxi BLA should be worth a nice gain even if FDA approval doesn’t come until 2023.)
• SPEX.SW 20%: Under-the-radar company resulting from the reverse-merger of (private) EnBiotix and POLN.SW. Has phase-3 program of inhaled antibiotic for CF patients. Plans to list on Nasdaq during 2022. (The symbol changed from POLN.SW to SPEX.SW at today’s open.)
• XENT 20%: Re-allocation vig; being acquired by MDT for cash.
• BMY 5%: Undervalued stock in my real portfolio.
• PFE 5%: Ditto. (Considerable upside even after 60% rise in 2021.)
• ASMB 5%: Well-funded and trading for only 65% of cash value! HBV program has been unimpressive, but they might get lucky.
• PRDS 5%: Protease inhibitor for COVID entering phase-1.
Thanks for asking.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.